Fate Therapeutics (FATE) Stock Forecast, Price & News

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last twelve months. There are currently 2 sell ratings, 13 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares.
View FATE analyst ratings or view top-rated stocks.

20 brokers have issued 1 year price targets for Fate Therapeutics' shares. Their FATE share price forecasts range from $5.00 to $65.00. On average, they expect the company's share price to reach $12.96 in the next year. This suggests a possible upside of 529.2% from the stock's current price.
View analysts price targets for FATE or view top-rated stocks among Wall Street analysts.

Fate Therapeutics' stock was trading at $10.09 at the start of the year. Since then, FATE stock has decreased by 79.6% and is now trading at $2.06.
View the best growth stocks for 2023 here.

Fate Therapeutics saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 24,290,000 shares, a decline of 12.1% from the August 31st total of 27,640,000 shares. Based on an average trading volume of 2,280,000 shares, the short-interest ratio is presently 10.7 days. Approximately 26.2% of the company's stock are short sold.
View Fate Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our FATE earnings forecast.

Fate Therapeutics, Inc. (NASDAQ:FATE) released its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, beating analysts' consensus estimates of ($0.58) by $0.04. The biopharmaceutical company had revenue of $0.93 million for the quarter, compared to the consensus estimate of $5.41 million. Fate Therapeutics had a negative net margin of 177.41% and a negative trailing twelve-month return on equity of 44.14%. The business's revenue for the quarter was down 95.0% on a year-over-year basis. During the same quarter last year, the company posted ($0.79) EPS.

iShares Genomics Immunology and Healthcare ETF holds 348,530 shares of FATE stock, representing 0.86% of its portfolio.

2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), Juno Therapeutics (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD).

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Fate Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.15%), State Street Corp (10.46%), JPMorgan Chase & Co. (2.77%), Geode Capital Management LLC (1.77%), Northern Trust Corp (1.27%) and Goldman Sachs Group Inc. (1.10%). Insiders that own company stock include Bahram Valamehr, Brian T Powl, Cindy Tahl, Daniel D Shoemaker, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, Mark Plavsic, Redmile Group, Llc, Shefali Agarwal, Yuan Xu and Yu-Waye Chu.
View institutional ownership trends.

Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FATE stock can currently be purchased for approximately $2.06.

Fate Therapeutics (NASDAQ:FATE) has a market capitalization of $203.03 million and generates $96.30 million in revenue each year. The biopharmaceutical company earns $-281,720,000.00 in net income (profit) each year or ($2.17) on an earnings per share basis.

The company employs 551 workers across the globe.

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.fatetherapeutics.com. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at christina@sternir.com.